{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:38:43Z","timestamp":1760783923111},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Optim Theory Appl"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s10957-015-0717-9","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T16:52:54Z","timestamp":1424969574000},"page":"326-341","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Stability and Controllability Issues in Mathematical Modeling of the Intensive Treatment of Leukemia"],"prefix":"10.1007","volume":"167","author":[{"given":"L.","family":"Berezansky","sequence":"first","affiliation":[]},{"given":"S.","family":"Bunimovich-Mendrazitsky","sequence":"additional","affiliation":[]},{"given":"B.","family":"Shklyar","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,2,27]]},"reference":[{"key":"717_CR1","unstructured":"World Cancer Research Fund International (WCRF International) statistics (2008). http:\/\/www.wcrf.org\/cancer_statistics\/world_cancer_statistics.php"},{"key":"717_CR2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D.: Statistics. CA Cancer J. Clin. 61, 69\u201390 (2011)","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"717_CR3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl, S., Talpaz, M., Estrov, Z., O\u2019Brien, S., Kurzrock, R., Kantarjian, H.: The biology of chronic myeloid leukemia. N. Engl. J. Med. 341(3), 164\u2013172 (1999)","journal-title":"N. Engl. J. Med."},{"key":"717_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","volume":"91","author":"BJ Druker","year":"2004","unstructured":"Druker, B.J.: Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1\u201330 (2004)","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"717_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker, B.J., Lydon, N.B.: Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Investig. 105(1), 3\u20137 (2000)","journal-title":"J. Clin. Investig."},{"key":"717_CR6","first-page":"225","volume":"2","author":"BJ Druker","year":"2003","unstructured":"Druker, B.J.: Overcoming resistance to imatinib by combining targeted agents. Mol. Cancer Ther. 2, 225\u2013226 (2003)","journal-title":"Mol. Cancer Ther."},{"key":"717_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","volume":"11","author":"V Nardi","year":"2004","unstructured":"Nardi, V., Azam, M., Daley, G.Q.: Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35\u201343 (2004)","journal-title":"Curr. Opin. Hematol."},{"issue":"3","key":"717_CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.beha.2009.08.001","volume":"22","author":"JM Goldman","year":"2009","unstructured":"Goldman, J.M.: Treatment strategies for CML. Best Pract. Res. Clin. Haematol. 22(3), 303\u2013313 (2009)","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"717_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1471-4906(00)01857-3","volume":"22","author":"JD Campbell","year":"2001","unstructured":"Campbell, J.D., Cook, G., Holyoake, T.L.: Evolution of bone marrow transplantation the original immunotherapy. Trends Immunol. 22(2), 88\u201392 (2001)","journal-title":"Trends Immunol."},{"issue":"2","key":"717_CR10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/imt.10.2","volume":"2","author":"V Vonka","year":"2010","unstructured":"Vonka, V.: Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2(2), 227\u2013241 (2010)","journal-title":"Immunotherapy"},{"issue":"2","key":"717_CR11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10428190400012029","volume":"46","author":"A Burchert","year":"2005","unstructured":"Burchert, A., Neubauer, A.: Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk. Lymphoma 46(2), 167\u2013175 (2005)","journal-title":"Leuk. Lymphoma"},{"key":"717_CR12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert, A., Muller, M.C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A., Hochhaus, A.: Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 28, 1429\u20131435 (2010)","journal-title":"J. Clin. Oncol."},{"key":"717_CR13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0895-7177(00)00143-6","volume":"32","author":"N Bellomo","year":"2000","unstructured":"Bellomo, N., Preziosi, L.: Modelling and mathematical problems related to tumour evolution and its interaction with the immune system. Math. Comput. Model. 32, 413\u2013452 (2000)","journal-title":"Math. Comput. Model."},{"key":"717_CR14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0165-2478(03)00023-3","volume":"86","author":"D Wodarz","year":"2003","unstructured":"Wodarz, D., Jansen, V.A.A.: A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology. Immunol. Lett. 86, 213\u2013227 (2003)","journal-title":"Immunol. Lett."},{"key":"717_CR15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1142\/S0218202504003799","volume":"14","author":"N Bellomo","year":"2004","unstructured":"Bellomo, N., Bellouquid, A., Delitala, M.: Mathematical topics on the modelling complex multicellular systems and tumour immune cells competition. Math. Models Methods Appl. Sci. 14, 1683\u20131733 (2004)","journal-title":"Math. Models Methods Appl. Sci."},{"key":"717_CR16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.physd.2005.06.032","volume":"208","author":"A d\u2019Onofrio","year":"2005","unstructured":"d\u2019Onofrio, A.: A general framework for modeling tumor\u2013immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Phys D. 208, 220\u2013235 (2005)","journal-title":"Phys D."},{"key":"717_CR17","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1142\/S0218202506001571","volume":"16","author":"A d\u2019Onofrio","year":"2006","unstructured":"d\u2019Onofrio, A.: Tumor\u2013immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy. Math. Models Methods Appl. Sci. 16, 1375\u20131401 (2006)","journal-title":"Math. Models Methods Appl. Sci."},{"key":"717_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00262-007-0387-z","volume":"57","author":"N Kronik","year":"2008","unstructured":"Kronik, N., Kogan, Y., Vainstein, V., Agur, Z.: Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol. Immunother. 57, 425\u2013439 (2008)","journal-title":"Cancer Immunol. Immunother."},{"key":"717_CR19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.mcm.2009.11.005","volume":"51","author":"A d\u2019Onofrio","year":"2010","unstructured":"d\u2019Onofrio, A., Gatti, F., Cerrai, P., Freschi, L.: Delay-induced oscillatory dynamics of tumour\u2013immune system interaction. Math. Comput. Model. 51, 572\u2013591 (2010)","journal-title":"Math. Comput. Model."},{"issue":"Suppl 4","key":"717_CR20","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1471-2105-13-S4-S8","volume":"13","author":"G Caravagna","year":"2012","unstructured":"Caravagna, G., Barbuti, R., d\u2019Onofrio, A.: Fine-tuning anti-tumor immunotherapies via stochastic simulations. BMC Bioinform. 13(Suppl 4), S8 (2012)","journal-title":"BMC Bioinform."},{"issue":"6","key":"717_CR21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood.V33.6.843.843","volume":"33","author":"PC Vincent","year":"1969","unstructured":"Vincent, P.C., Cronkite, E.P., Greenberg, M.L., Kirsten, C., Schiffer, L.M., Stryckmans, P.A.: Leukocyte kinetics in chronic myeloid leukemia. I. DNA synthesis time in blood and marrow myelocytes. Blood 33(6), 843\u2013850 (1969)","journal-title":"Blood"},{"key":"717_CR22","first-page":"2084","volume":"51","author":"AS Fokas","year":"1991","unstructured":"Fokas, A.S., Keller, J.B., Clarkson, B.D.: A mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer 51, 2084\u20132091 (1991)","journal-title":"Cancer"},{"key":"717_CR23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jtbi.2003.11.024","volume":"227","author":"H Moore","year":"2004","unstructured":"Moore, H., Li, N.K.: A mathematical model of chronic myelogenous leukemia (CML) and T cell interaction. J. Theor. Biol. 227, 513 (2004)","journal-title":"J. Theor. Biol."},{"key":"717_CR24","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","volume":"102","author":"N Komarova","year":"2005","unstructured":"Komarova, N., Wodarz, D.: Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. USA 102, 9714\u20139719 (2005)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"717_CR25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor, F., Hughes, T., Iwasa, Y., Branford, S., Shah, N., Sawyers, C., Nowak, M.: Dynamics of chronic myeloid leukemia. Nature 435, 1267\u20131270 (2005)","journal-title":"Nature"},{"key":"717_CR26","doi-asserted-by":"crossref","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","volume":"4","author":"P Kim","year":"2008","unstructured":"Kim, P., Lee, P., Levy, D.: Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol. 4, e1000095 (2008)","journal-title":"PLoS Comput. Biol."},{"key":"717_CR27","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s11538-010-9553-0","volume":"73","author":"D Paquin","year":"2011","unstructured":"Paquin, D., Kim, P.S., Lee, P.P., Levy, D.: Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia. Bull. Math. Biol. 73, 1082\u20131100 (2011)","journal-title":"Bull. Math. Biol."},{"key":"717_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","volume":"210","author":"S Nanda","year":"2007","unstructured":"Nanda, S., Moore, H., Lenhart, S.: Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math. Biosci. 210, 143 (2007)","journal-title":"Math. Biosci."},{"key":"717_CR29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mbs.2010.06.005","volume":"227","author":"B Ainseba","year":"2010","unstructured":"Ainseba, B., Benosman, C.: Optimal control for resistance and suboptimal response in CML. Math. Biosci. 227, 81\u201393 (2010)","journal-title":"Math. Biosci."},{"key":"717_CR30","first-page":"257","volume":"217","author":"L Berezansky","year":"2012","unstructured":"Berezansky, L., Bunimovich-Mendrazitsky, S., Domoshnitsky, A.: A mathematical model with time-varying delays in the combined treatment of chronic myeloid leukemia. Adv. Differ. Equ. 217, 257\u2013266 (2012)","journal-title":"Adv. Differ. Equ."},{"key":"717_CR31","first-page":"7067","volume":"48","author":"L Norton","year":"1988","unstructured":"Norton, L.: A Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067\u20137071 (1988)","journal-title":"Cancer Res."},{"key":"717_CR32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/bjc.1964.55","volume":"18","author":"AK Laird","year":"1964","unstructured":"Laird, A.K.: Dynamics of tumor growth. Br. J. Cancer. 18, 490\u2013502 (1964)","journal-title":"Br. J. Cancer."},{"key":"717_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.mbs.2004.06.003","volume":"191","author":"A d\u2019Onofrio","year":"2004","unstructured":"d\u2019Onofrio, A., Gandolfi, A.: Tumor eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. Math. Biosci. 191, 159\u2013184 (2004)","journal-title":"Math. Biosci."},{"key":"717_CR34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2184.2009.00595.x","volume":"42","author":"A d\u2019Onofrio","year":"2009","unstructured":"d\u2019Onofrio, A., Gandolfi, A., Rocca, A.: The dynamics of tumour\u2013vasculature interaction suggests low dose, time-dense antiangiogenic scheduling. Cell Prolif. 42, 317\u2013329 (2009)","journal-title":"Cell Prolif."},{"key":"717_CR35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.mcm.2007.02.032","volume":"47","author":"A d\u2019Onofrio","year":"2008","unstructured":"d\u2019Onofrio, A.: Metamodeling tumour\u2013immune system interaction, tumour evasion and immunotherapy. Math. Comput. Model. 47, 614\u2013637 (2008)","journal-title":"Math. Comput. Model."},{"key":"717_CR36","volume-title":"Qualitative Theory of Optimal Processes","author":"R Gabasov","year":"1972","unstructured":"Gabasov, R., Kirillova, F.: Qualitative Theory of Optimal Processes. M. Nauka, Moscow (1972)"},{"issue":"1","key":"717_CR37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2014.01.033","volume":"347","author":"M Breccia","year":"2014","unstructured":"Breccia, M., Alimena, G.: Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett. 347(1), 22\u201328 (2014)","journal-title":"Cancer Lett."},{"key":"717_CR38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.beha.2009.09.002","volume":"22","author":"E Jabbour","year":"2009","unstructured":"Jabbour, E., Fava, C., Kantarjian, H.: Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best. Pract. Res. Clin. Haematol. 22, 395\u2013407 (2009)","journal-title":"Best. Pract. Res. Clin. Haematol."}],"container-title":["Journal of Optimization Theory and Applications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10957-015-0717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10957-015-0717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10957-015-0717-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T09:47:28Z","timestamp":1598780848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10957-015-0717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,27]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s10957-015-0717-9","relation":{},"ISSN":["0022-3239","1573-2878"],"issn-type":[{"value":"0022-3239","type":"print"},{"value":"1573-2878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,27]]}}}